case_images: PMC10701292_01
case_images: Clinical course in case 1. Black figure size represents the degree of symptoms of each situation. Red arrows represent the occurrence of short burst, while blue arrow represents the performance of BT. FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s. ACT, asthma control test; BT, bronchial thermoplasty; ICS, inhaled corticosteroid; IGA, investigator global assessment; IgE, immunoglobulin E; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; PSL, prednisolone.
case_images: RCR2-12-e01266-g001.jpg
case_images: PMC10701292_01_RCR2-12-e01266-g001.jpg
case_images: rcr21266-fig-0001
case_images: At present, he continues benralizumab and dupilumab treatment (Figure 1).
case_images: PMC10701292_02
case_images: Clinical course in case 2. Black figure size represents the degree of symptoms of each situation. Red arrows represent the occurrence of short burst. FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s. ACT, asthma control test; ICS, inhaled corticosteroid; IGA, investigator global assessment; IgE, immunoglobulin E; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid.
case_images: RCR2-12-e01266-g003.jpg
case_images: PMC10701292_02_RCR2-12-e01266-g003.jpg
case_images: rcr21266-fig-0002
case_images: This combined regimen showed successful asthma management, making his current maintenance of omalizumab and dupilumab (Figure 2).